ArticleCancer cell2024
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07026669 (A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer), which is not on this map. Cited by 105 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 2 pooled it
27.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer: A Prospective, Non-interventional Study
Who cites it
105 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Biomarkers in medicine · 2025Pooled it
- Circulating proteins associated with histological subtypes of lung cancer from genetic and population-based perspectives.PLoS genetics · 2025Pooled it
- Dalpiciclib plus endocrine therapy in women with HRNature cancer · 2026Trial
- ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer.Nature communications · 2026Trial
- Application and mechanistic research of novel therapeutic strategies in cisplatin-resistant small cell lung cancer.Annals of medicine · 2026Review
- Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer.The Journal of clinical investigation · 2026Article
- Review
- Consolidated Evidence and New Frontiers of Liquid Biopsy in Lung Cancer: A Narrative Review.Cells · 2026Review
- Pattools‑implemented methylation vector analysis reveals aberrant subtype‑specific methylation in lung cancer across tissue and plasma cfDNA.Clinical and translational medicine · 2026Article
- Development and preliminary validation of plasma cell-free DNA methylation-based diagnostic prediction model for colorectal cancer detection.Journal of gastrointestinal oncology · 2026Article
- Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology.Virchows Archiv : an international journal of pathology · 2026Review
- YAP1 Defines an Emergent, Plastic Population of Relapsed SCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- Epigenetics in lung cancer precision medicine: from bench to bedside-a narrative review.Translational lung cancer research · 2026Review
- [Expert Consensus on Immunotherapy for Extensive-stage Small Cell Lung Cancer Based on Molecular Subtyping].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Methylation-based liquid biopsy facilitates early detection of small cell transformation in ALK-rearranged non-small cell lung cancer.The oncologist · 2026Article
- Decoding Small Cell Lung Cancer: Molecular Subtypes, Surface Antigens, and the Target-Modality Problem.Cancers · 2026Review
- Biological basis and clinical translation prospects of circulating cell-free DNA in precision management of breast cancer (Review).Oncology letters · 2026Review
- Research progress on immune microenvironment and biomarkers of small cell lung cancer.Journal of thoracic disease · 2026Review
- Extracellular vesicle and particle biomarkers in cancer: a machine learning blueprint for liquid biopsy.Journal of nanobiotechnology · 2026Review
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 9 institutions in 7 countries.
Simon HeekeDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carl M GayDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Marcos R EstecioEpigenetic and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hai TranDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Benjamin B MorrisDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bingnan ZhangDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ximing TangDepartment of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maria Gabriela RasoDepartment of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pedro RochaMedical Oncology Department, Hospital del Mar, Barcelona, Spain.
Siqi LaiDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center UTHealth Houston, Houston, TX, USA.
Edurne ArriolaMedical Oncology Department, Hospital del Mar, Barcelona, Spain.
Paul HofmanLaboratory of Clinical and Experimental Pathology, IHU RespirERA, Nice Hospital, University Côte d'Azur, Nice, France.
Veronique HofmanLaboratory of Clinical and Experimental Pathology, IHU RespirERA, Nice Hospital, University Côte d'Azur, Nice, France.
Prasad KopparapuDepartment of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Christine M LovlyDepartment of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Kyle ConcannonDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Luana Guimaraes De SousaDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Whitney Elisabeth LewisDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kimie KondoEpigenetic and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xin HuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Azusa TanimotoDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Natalie I VokesDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Monique B NilssonDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Allison StewartDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maarten JansenPulmonary Department, Ziekenhuisgroep Twente, Hengelo, the Netherlands.
Ildikó HorváthNational Korányi Institute of Pulmonology, Budapest, Hungary.
Mina Gaga7th Respiratory Medicine Department, Athens Chest Hospital, Athens, Greece.
Vasileios Panagoulias2nd Respiratory Medicine Department, Athens Chest Hospital, Athens, Greece.
Yael RavivDepartment of Medicine, Pulmonology, Institute, Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel.
Danny FrumkinNucleix Ltd. Rehovot, Israel.
Adam WasserstromNucleix Ltd. Rehovot, Israel.
Aharona ShualiNucleix Ltd. Rehovot, Israel.
Catherine A SchnabelNucleix Inc, San Diego, CA, USA.
Yuanxin XiDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lixia DiaoDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Qi WangDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianjun ZhangDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peter Van LooDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Francis Crick Institute, London, UK.
Jing WangDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ignacio I WistubaDepartment of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lauren A ByersDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: lbyers@mdanderson.org.
John V HeymachDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jheymach@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USNucleix (Israel) · ILCentre Hospitalier Universitaire de Nice · FRHospital Del Mar · ESVanderbilt University Medical Center · USBen-Gurion University of the Negev · ILChest Diseases Hospital · KWOrszágos Korányi Tbc és Pulmonológiai Intézet · HUZiekenhuis Groep Twente · NL
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4MCoordinating center for the NCI small cell lung cancer research consortiumU24CA213274 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Lauren Averett Byers, JOHN D. MINNA · 2017 to 2026
$12.9MSingle-Cell Biology and Data Analysis Shared Resource (SCB-DA SR)U54CA217450 · NCI · VANDERBILT UNIVERSITY · PI WEAVER, ALISSA M · 2018 to 2022
$8.5MECOG-ACRIN Thoracic Malignancies Integrated Translational Science CenterUG1CA233259 · NCI · EMORY UNIVERSITY · PI CARBONE, DAVID P., LEAL, TICIANA · 2019 to 2025
$5.1MTherapeutic strategies for targeting PARP1 in small cell lung cancerR01CA207295 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Lauren Averett Byers · 2016 to 2026
$3.7MNovel therapeutic approaches for enhancing anti-tumor immunity in SCLCU01CA213273 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BYERS, LAUREN AVERETT, HEYMACH, JOHN V. · 2017 to 2021
$3.0MMolecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic responseU01CA256780 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BYERS, LAUREN AVERETT, HEYMACH, JOHN V. · 2021 to 2025
$3.0MIntegrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancerR01CA276178 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Natalie Vokes, Jia Wu · 2023 to 2026
$2.6MPhenotype Interactions in SCLC Development and DetectionU01CA224276 · NCI · VANDERBILT UNIVERSITY · PI WEAVER, ALISSA M · 2018 to 2022
$1.6MModeling tumor heterogeneity, to develop new therapeutic strategies for treatment of resistant small cell lung cancerR50CA243698 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Catherine Allison Stewart · 2020 to 2026
$701kTargeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)R50CA265307 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NILSSON, MONIQUE B · 2021 to 2025
$585kMedical Research Council CC2008NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA207295NCI NIH HHS R01 CA276178NCI NIH HHS R50 CA243698NCI NIH HHS R50 CA265307NCI NIH HHS U01 CA213273NCI NIH HHS U01 CA224276NCI NIH HHS U01 CA256780NCI NIH HHS U24 CA213274NCI NIH HHS U54 CA217450NCI NIH HHS UG1 CA233259Wellcome Trust CC2008
Abstract
Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct transcriptional subtypes, but implementing subtyping in the clinic has remained challenging, particularly due to limited tissue availability. Given the known epigenetic regulation of critical SCLC transcriptional programs, we hypothesized that subtype-specific patterns of DNA methylation could be detected in tumor or blood from SCLC patients. Using genomic-wide reduced-representation bisulfite sequencing (RRBS) in two cohorts totaling 179 SCLC patients and using machine learning approaches, we report a highly accurate DNA methylation-based classifier (SCLC-DMC) that can distinguish SCLC subtypes. We further adjust the classifier for circulating-free DNA (cfDNA) to subtype SCLC from plasma. Using the cfDNA classifier (cfDMC), we demonstrate that SCLC phenotypes can evolve during disease progression, highlighting the need for longitudinal tracking of SCLC during clinical treatment. These data establish that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy.
Indexed as
Cell-Free Nucleic AcidsLung NeoplasmsSmall Cell Lung CarcinomaBiomarkers, TumorDNA MethylationEpigenesis, GeneticHumansBiomarkers, TumorCell-Free Nucleic AcidsbiomarkercfDNActDNADNA methylationepigeneticsgene expressionliquid biopsylung cancerSCLCsubtyping
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT07026669ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.